Medicus Pharma licensed exclusive worldwide rights to Pfizer’s early clinical-stage CD228-targeted antibody-drug conjugate, CD228V/PF-08046031, for human disease. Medicus paid $12 million upfront, owes $15 million on the first anniversary, received $2 million in restricted…
Two Phase 3 trials of oral ritlecitinib in nonsegmental vitiligo met their U.S. co-primary Week-52 endpoints for facial and total-body repigmentation. Pfizer plans global submissions for adults. The topline release establishes pivotal success but…
Pfizer has discontinued a Phase 1 immunostimulatory drug-conjugate program in oncology, highlighting challenges in developing next-generation targeted delivery modalities.
Pfizer announced the closure of its South San Francisco research site, citing underutilization and broader pressures in the biotech funding environment. The move reflects ongoing post-pandemic restructuring across large pharmaceutical companies and signals shifts…
